EVALUATION OF ANTI-DIABETIC POTENTIAL OF IXORA PAVETTAIN STREPTOZOTOCIN INDUCED DIABETIC RATS
Keywords:
Ixorapavetta, Anti-diabetic, Streptozotocin, OGTTAbstract
Objective: Evaluation of anti-diabetic potential ofIxorapavetta in streptozotocin induced diabetic rats
Methods: Diabetes was induced by thesingle dose of streptozotocin (65 mg/kg body weight i. p.) to female Wistarrats. Diabetic rats were stabilized for six day and from seventh day butenolic fraction of Ixorapavetta(BIP) was administered at a dose of 250 mg/kg, p. o. and 500 mg/kg for 3 weeks. Glibenclamide 10 mg/kg P. O. was used as a standard. The effects of BIP and standard drug on following parameters were recorded - body weight, blood glucose and various biochemical parameters like serum lipid profile eg. total cholesterol (TC) and triglyceride (TG), HDL-C, LDL-C and VLDL. At the end of the study oxidative stress markers like CAT, GSH, and lipid peroxidation were analyzed in the pancreases. Histopathological changes were studied in pancreases of representative animals of the each group.
Results: Administration of butenolic fractionof Ixorapavetta(BIP) at a dose of 250 mg/kg, p. o. and 500 mg/kg, p. o did not show any significant change in blood glucose level of normoglycemic rats, whereas, oral glucose tolerance test depicted significant (P<0.001) reduction in blood glucose level at 30 to 60 min. In streptozotocininduced diabetic rats, BIP was found significantly beneficial in controlling elevated blood glucose level and serum lipid parameters. The findings were strengthening by improved antioxidant status in diabetic rats as well as protection towards pathological damage of pancreases. The results showed by 500 mg/kg of butenol fractionof Ixorapavettawere comparable with standard treatment of Glibenclamide 10 mg/kg.
Conclusion: Butenolfractionof Ixorapavettapossessanti-diabetic action in streptozotocin induced diabetic rats.
Â
Downloads
References
Kumar PJ, Clark M. Textbook of clinical medicine. London: Saunders publication; 2002.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabeties for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
Bearse MAJ, Han T, Schneck ME. Local multifocal oscillatory potential abnormalities diabetes and early diabetic retinopathy. Invest Ophthal Vis Sci 2004;45:3259-65.
Rajesh K, Dinesh KP, Satyendra KP, Kirshnamurthy S, Siva H. Antidiabetic activity of alcoholic leaves extract of Alangiumlamarckii Thwaites on streptozotocin-nicotinamide induced type 2 diabetic rats. Asia Pacific J Trop Med 2011;4(11):904-9.
Tripathi KD. Essentials of medical pharmacology. 3rd Ed. New Delhi: Jaypee Brothers, Medical publishers; 2003. p. 532-42.
Kumar S, Kumar V, Prakash O. Antidiabetic and anti-lipidemic effects of Cassia siamea leaves extract in streptozotocin induced diabetic rats. Asia Pacific J Trop Med 2010:871-3.
Verma S, Singh SP. Current and future status of herbal medicines. Vet World 2008;1(11):347-50.
Nadkarni AK, Nadkarni KM. Indian Materia Medica. 3rd Ed. Mumbai: Popular Prakashan; 1986. p. 925.
Madhava CK, Sivaji K, Tulasi RK. Flowering plants of chittoor district of andhra pradesh. 2nd Ed. Tirupathi: Student offset printers; 2008. p. 158.
Srinivas K, Celestin BRV. Antimicrobial activity of flowers of ixorapavettaandr. Inter. J Phytother 2013;3(1):15-7.
Srinivas K, Celestin BRV. Antioxidant activity of Ixorapavettaandr. Int J Res Pharm Nano Sci 2013;2(2):191-4.
Srinivas K, Celestin BRV. Antiulcer activity of Ixorapavetta. Int J Curr Pharm Res 2011;3(2):1-2.
Mondal S, Raja S, Prasad PNVSS, Suresh P. Investigations of Phytochemical, Analgesic, Anti-Inflammatory and Antipyretic Effects of Ixora Pavetta Andrews Leaf. Am J Pharm Tech Res 2013;3(6).
Kanhere RS, Reddy KR, Jayaveera KN. Evaluation of anti-obesity potential of Ixorapavetta against high fat diet induced obesity in wistar rats. Int J Pharm Res Bio Sci 2014;3(4):594-605.
Kanhere RS, Anjana A, AmbuJ, Sumitra M, Nazeer KFH. Neuroprotective effect of terpenoid fraction from hygrophila auriculata (Schum) Heine In Transiant Global Cerebral Ischemia In Rats. Pharm Bio 2013;51(2);181-9.
Hugo A, Sonja R, Bernhard S, Frantisek S. Isolation and characterization of normal and variant erythrocyte catalase and their subunits. Eur J Biochem 1974;48(1);137–45.
Moron MS, Dsepierre JW, Manerwik KB. Levels of giutathione, glutathione reductase and glutathione–s–transferase activities in rat lung and liver. Biochim Biophys Acta 1979;582:67-8.
Slater TF, Sawyer RC. Stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro: General features of systems used. Biochem J 1971;123:805-14.
Mohammad AE, Razeih Y. Hypoglycemic effect of Teucriumpolium studies with rat pancreatic islets. J Ethanopharm 2004;95:27-30.
Gilman AG, Rall TW, Nles AS, Tayer P. The pharmacological basis of therapeutics. 18th Ed. New York: Pergamen press; 1990. p. 1317-22, 1463-95.
Jarald EE, Joshi SB, Jain DC. Antidiabetic activity of flower buds of Micheliachampaca Linn. Indian J Pharm 2008;40(6):256-60.
Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM. Antihyperglycemiceffects of three extracts from Momordicacharantia. J Ethnopharm 2003;88(1):107-11.
Krishan K, Vijayalakshmi NR, Helen A. Methanolic extract of CostusIgneus alleviates dyslipidemia in diabetic rats. Asian J Pharm Clin Res 2011;4(1):154-7.
Nakhaee A, Bokaeian M, Saravani M, Farhangi A, Akbarzadeh A. Attenuation of oxidative stress in streptozotocin-induced diabetic rats by Eucalyptus globules. Indian J Clin Biochem 2009;24(4):419-25.